Fermentation-based anti-infective APIs, injectables and contract manufacturing
Xellia Pharmaceuticals is a Copenhagen-based anti-infectives manufacturer whose stack is dominated by analytical lab tooling (HPLC, UPLC, LC-MS/MS, LIMS) and plant automation (WinCC), backed by on-prem virtualization and storage (VMware, Hyper-V, NetApp ONTAP, Cloudian). Hiring is manufacturing- and quality-led and concentrated in Hungary, with job posts repeatedly flagging GMP inspection readiness, recalls and regulatory deficiency letters.
Xellia Pharmaceuticals produces anti-infective medicines using fermentation-based manufacturing, with a focus on non-beta-lactam molecules. Its portfolio spans active pharmaceutical ingredients, finished dosage forms, injectables and critical care products, and it also offers contract manufacturing. The company is headquartered in Copenhagen, Denmark, traces its roots to 1903, and is privately held with 1,001–5,000 employees. Current hiring activity centers on its operations in Hungary.
Xellia uses lab and analytical tools like HPLC, UPLC, LC-MS/MS and LIMS, Siemens WinCC for automation, AutoCAD, and infrastructure including VMware, Hyper-V, NetApp ONTAP, IBM Storage, Cloudian and QNAP.
Current openings are in Hungary, focused mainly on manufacturing and quality, with additional roles in engineering, regulatory, logistics, legal, HR and operations.
Job posts point to manufacturing site technical transfers, process and cleaning validation, new product implementation, ASMF/DMF/CEP preparation, global quality projects and warehouse temperature mapping.
Other companies in the same industry, closest in size
Xellia Pharmaceuticals's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.